Bolt Biotherapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 23

Employees

  • Stock Symbol
  • BOLT

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.96
  • (As of Friday Closing)

Bolt Biotherapeutics General Information

Description

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Contact Information

Website
www.boltbio.com
Formerly Known As
Bolt Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 900 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 900 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bolt Biotherapeutics Stock Performance

As of 20-Nov-2026, Bolt Biotherapeutics’s stock price is $4.96. Its current market cap is $12.8M with 2.61M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.96 $5.06 $3.10 - $7.78 $12.8M 2.61M 255K -$13.93

Bolt Biotherapeutics Financials Summary

As of 30-Sep-2026, Bolt Biotherapeutics has a trailing 12-month revenue of $2.53M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 11,115 2,175 (15,141) (56,345)
Revenue 2,531 7,695 7,690 7,876
EBITDA (26,451) (34,572) (66,573) (74,296)
Net Income (26,180) (33,376) (63,118) (69,197)
Total Assets 35,591 56,748 99,632 159,784
Total Debt 20,889 22,958 25,209 20,219
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bolt Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatmen
Drug Discovery
Redwood City, CA
23 As of 2025

Redwood City, CA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bolt Biotherapeutics Competitors (43)

One of Bolt Biotherapeutics’s 43 competitors is Jasper Therapeutics, a Formerly VC-backed company based in Redwood City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Jasper Therapeutics Formerly VC-backed Redwood City, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Zymeworks Formerly VC-backed Vancouver, Canada
You’re viewing 5 of 43 competitors. Get the full list »

Bolt Biotherapeutics Patents

Bolt Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026055185-A1 Sting agonist immunoconjugates and uses thereof Pending 04-Sep-2024
WO-2026050214-A1 Anti-claudin, tlr agonist immunoconjugates and uses thereof Pending 27-Aug-2024
WO-2026050213-A8 Tlr agonist immunoconjugates and uses thereof Pending 27-Aug-2024
WO-2024216089-A1 Anti-dectin-2 antibody combination therapy Inactive 13-Apr-2023
WO-2024186626-A1 Aza-bicyclic sting agonist immunoconjugates, and uses thereof Inactive 03-Mar-2023 A61K47/6835
To view Bolt Biotherapeutics’s complete patent history, request access »

Bolt Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bolt Biotherapeutics Acquisitions (1)

Bolt Biotherapeutics’s most recent deal was a Reverse Merger with Prana Therapies. The deal was made on 23-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Prana Therapies 23-Oct-2026 Reverse Merger Drug Discovery
To view Bolt Biotherapeutics’s complete acquisitions history, request access »

Bolt Biotherapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.07 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Bolt Biotherapeutics’s complete esg history, request access »

Bolt Biotherapeutics FAQs

  • When was Bolt Biotherapeutics founded?

    Bolt Biotherapeutics was founded in 2015.

  • Where is Bolt Biotherapeutics headquartered?

    Bolt Biotherapeutics is headquartered in Redwood City, CA.

  • What is the size of Bolt Biotherapeutics?

    Bolt Biotherapeutics has 23 total employees.

  • What industry is Bolt Biotherapeutics in?

    Bolt Biotherapeutics’s primary industry is Drug Discovery.

  • Is Bolt Biotherapeutics a private or public company?

    Bolt Biotherapeutics is a Public company.

  • What is Bolt Biotherapeutics’s stock symbol?

    The ticker symbol for Bolt Biotherapeutics is BOLT.

  • What is the current stock price of Bolt Biotherapeutics?

    As of 20-Nov-2026 the stock price of Bolt Biotherapeutics is $4.96.

  • What is the current market cap of Bolt Biotherapeutics?

    The current market capitalization of Bolt Biotherapeutics is $12.8M.

  • What is Bolt Biotherapeutics’s current revenue?

    The trailing twelve month revenue for Bolt Biotherapeutics is $2.53M.

  • Who are Bolt Biotherapeutics’s competitors?

    Jasper Therapeutics, Adaptimmune Therapeutics, CytomX Therapeutics, Kite Pharma, and Zymeworks are some of the 43 competitors of Bolt Biotherapeutics.

  • What is Bolt Biotherapeutics’s annual earnings per share (EPS)?

    Bolt Biotherapeutics’s EPS for 12 months was -$13.93.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process